Anivance AI Corporation
- Company typePrivate
- Founded2024
- HeadquartersHsinchu, Taiwan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Anivance AI Corporation firmographics
Firmographics- Name
- Anivance AI Corporation
- Legal name
- Anivance AI Corporation
- Website
- https://anivance.io
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Anivance AI Corporation industry classification
Industry- Product category
- Drug Discovery Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industries
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Anivance AI Corporation is headquartered
LocationHeadquarters
- HQ city
- Hsinchu
- HQ country
- Taiwan
- HQ region
- Asia
Offices1 record
Markets served
Anivance AI Corporation business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Marketing channels1 record
Anivance AI Corporation product offering
Product offeringCore offering
Anivance AI Corporation develops AI-integrated organ-on-chip technology for pharmaceutical drug development and preclinical toxicology testing. Its core product is an Inhalation Lung Organ Chip Platform that combines biological organ modeling with artificial intelligence to simulate human lung responses for inhalation toxicity assessment, supporting both new drug development and environmental toxicology evaluation.
Product overview
Anivance AI is a Taiwanese startup specializing in AI organ chips for drug development. The company's core offering is the Inhalation Lung Organ Chip Platform, which combines organ-on-chip technology with artificial intelligence to provide human-relevant data for pharmaceutical research and toxicology assessment. The platform has been selected for international validation through the FNIH NAMs pilot program.
Differentiator
Problem solved
Functional benefit
Products and services
- Inhalation Lung Organ Chip Platform An AI-powered lung organ chip platform designed for inhalation toxicity assessment in drug development and environmental toxicology evaluation. Uses human data-based organ chips combined with artificial intelligence to simulate lung responses. The platform serves pharmaceutical companies, biotechnology firms, and regulatory agencies conducting toxicology testing and drug safety evaluation.
Quantifiable outcome
- Selected among 4 out of 64 global proposals for FNIH NAMs pilot program
Companies that use Anivance AI Corporation
Customer profileSegments2 records
Ideal customer profiles2 records
Anivance AI Corporation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature2 records
Anivance AI Corporation partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and minor.
- Foundation for the National Institutes of Health (FNIH)flagshipAnivance AI's Inhalation Lung Organ Chip Platform was selected for the FNIH global pilot program for new methodologies, out of 64 global proposals with only 4 ultimately selected. The company became the first from Taiwan selected for the FNIH NAMs pilot in inhalation toxicity assessment, with the platform to be included in international validation frameworks for drug development and environmental toxicology.
- Two Industry Leaders (unspecified)coreJiu Lang Zhi Yi (Anivance AI) completed seed round financing and partnered with two industry leaders to advance organ chip technology and expand smart healthcare global footprint.
- Hsinchu Science ParkminorAnivance AI participated in Hsinchu Science Park-led programs, including the Singapore SWITCH 2025 exhibition, where the company engaged in ecosystem integration activities and connected with local venture capital and academia.
- Taiwan Tech Arena (TTA) / National Science and Technology Council (NSTC)minorThe company participates in TTA and NSTC programs designed to support Taiwanese deep tech and AI startups in reaching international markets.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Anivance AI Corporation competitors and assessment
Company assessmentDirect peers
- Emulate, Inc. Leading commercial organ-on-chip company (Liver-Chip, Lung-Chip, Brain-Chip) serving pharma R&D and toxicology. Direct competitor in the same preclinical organ-chip category, with deeper pharma penetration and broader organ portfolio.
- CN Bio Innovations: Developer of PhysioMimix single- and multi-organ microphysiological systems used for ADME and toxicology studies by pharma. Closely comparable product offering and customer base, with established FDA/NIH engagement.
- Mimetas: Organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models in toxicology and disease modeling. Comparable product category and pharma customer base, with similar AI/predictive-biology ambitions.
- TissUse GmbH: Berlin-based organ-on-chip company developing multi-organ 'human-on-a-chip' platforms for drug development and cosmetics testing. Direct competitor in microphysiological systems with overlapping toxicology use cases.
- Hesperos, Inc. Developer of multi-organ human-on-a-chip systems used for toxicology and efficacy testing, particularly in rare disease and IND-enabling studies. Comparable organ-chip technology targeting the same pharma preclinical workflow.
- InSphero AG: 3D microtissue and organoid platform provider for toxicology and disease modeling serving pharma R&D. Comparable in offering human-relevant in vitro alternatives for preclinical toxicology assessment.
- SynVivo, Inc. Provides microfluidic organ-on-chip platforms (including lung and vascular models) for drug delivery and toxicology studies. Directly comparable microphysiological technology for preclinical research.
Emerging players
- AxoSim, Inc. Specialized in nerve-on-a-chip platforms for neurotoxicology and neuroscience drug development. Comparable technology stack and customer type, though focused on neural applications rather than inhalation.
- NETRI: France-based organ-on-chip company using microfluidic devices with neural and organ models for pharma screening. Comparable technology and customer profile, with narrower organ focus similar to Anivance.
Broad incumbents
- Bico Group (CELLINK): Bioconvergence incumbent offering bioprinters, organ-on-chip, and related lab automation tools. Overlaps with Anivance's organ-chip space but operates at much broader scale across multiple life-science workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights6 records
Customer concentration
Anivance AI Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anivance AI Corporation leadership team
Management profileNumber of profiles
Profiles5 records
Anivance AI Corporation funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anivance AI Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anivance AI Corporation
What does Anivance AI Corporation do?
Anivance AI Corporation develops AI-integrated organ-on-chip technology for pharmaceutical drug development and preclinical toxicology testing. Its core product is an Inhalation Lung Organ Chip Platform that combines biological organ modeling with artificial intelligence to simulate human lung responses for inhalation toxicity assessment, supporting both new drug development and environmental toxicology evaluation.
Is Anivance AI Corporation a public or private company?
Anivance AI Corporation is a private company. It is classified as venture growth investor backed and is currently operating.
When was Anivance AI Corporation founded?
Anivance AI Corporation was founded in 2024. It employs 11 to 50 people.
Where is Anivance AI Corporation based?
Anivance AI Corporation is headquartered in Hsinchu, Taiwan, in the Asia region.
Who are Anivance AI Corporation's main competitors?
Direct peers on record are Emulate, Inc., CN Bio Innovations, Mimetas, TissUse GmbH, Hesperos, Inc., InSphero AG and SynVivo, Inc.. Emerging players are AxoSim, Inc. and NETRI. Bico Group (CELLINK) is listed as a broad incumbent.
Does Anivance AI Corporation have an API?
No public API is recorded for Anivance AI Corporation.
What industry is Anivance AI Corporation in?
Anivance AI Corporation's product category is Drug Discovery Technology. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip). Its NAICS code is 541714 and its SIC code is 8731.